Clinical Trials Logo

Clinical Trial Summary

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in radiation-induced brain injury.

Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University / Yameitang.

Primary outcome measure: The primary endpoint is the brain injury remission at week 15. In brief, the brain lesion will be evaluated by using brain MRI scan before and after thalidomide regimen. The clinical efficacy is defined as ≥ 25% reduction in brain edema volume on FLAIR images at week 15, as compared with that before thalidomide usage.


Clinical Trial Description

There is no acknowledged and effective standard treatment for radiation-induced brain injury (RI). Glucocorticoids and bevacizumab during acute period are optional ways to reduce the brain edema. However, glucocorticoids and bevacizumab are unsuitable or ineffective for some patients, especially in the early stage of RI. The investigators supposed that angiogenesis might play a key role in the pathogenesis of RI, and that thalidomide, as an antiangiogenic drug, would reduce immature angiogenesis and improve vessel maturation in RI.

Primary objectives: This phase II clinical trial aims to evaluate the indications, therapeutic effects and safety of thalidomide in radiation-induced brain injury.

OUTLINE: This is a phase II, open-label, single arm clinical trial. Patients are enrolled and administrated with thalidomide. Thalidomide is supplied as 25 mg per pill to be taken by mouth.

Arm І: Patients receive thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03208413
Study type Interventional
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Yamei Tang, M.D., Ph.D.
Phone 86-13556001992
Email yameitang@hotmail.com
Status Recruiting
Phase Phase 2
Start date July 19, 2017
Completion date July 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Completed NCT02985164 - Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography Phase 3
Recruiting NCT04152681 - Effect and Safety of Apatinib on Radiation-Induced Brain Injury Phase 2
Recruiting NCT04818099 - Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy Phase 3
Completed NCT03667859 - Vaginal Elasticity Assessment Before and After Brachytherapy/Pelvic Radiation
Terminated NCT03660618 - LSFG-SKIN, Laser Speckle Flowgraphy N/A
Completed NCT00725244 - Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias Phase 4
Completed NCT00001523 - Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation N/A
Recruiting NCT03907371 - The Effect of Donepezil in Radiotherapy-related Cognitive Impairment. Phase 2
Not yet recruiting NCT05063773 - Novel Wireless Mixed Reality Headset for Image Guidance in Cardiac Catheterization Laboratory N/A
Completed NCT00001437 - Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis Phase 2
Recruiting NCT06325982 - Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury N/A
Completed NCT02972736 - RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study
Completed NCT02104271 - Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. Phase 2
Terminated NCT00134628 - Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries Phase 3
Completed NCT03961217 - Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes